NCT06932146: An ongoing trial by Lilac Therapeutics, Inc.
This trial is ongoing. It must report results 5 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06932146 |
|---|---|
| Title | A Phase 2a Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effects of LLX-424 in Patients With a History of Kidney Stones |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 23, 2025 |
| Completion date | Sept. 30, 2025 |
| Required reporting date | Sept. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |